Every 10-Q that ORGANON & CO (OGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OGN filings page.
Organon & Co. reported Q2 2026 revenue of $1,558 million, down 2% year over year, and six‑month revenue of $3,018 million, down 3%, with foreign exchange providing a modest tailwind. Q2 net income was $108 million, while six‑month net income rose to $254 million. The effective tax rate increased to 41.3% for the quarter and 36.0% year to date, reflecting foreign earnings mix, U.S. interest deductibility limits and impacts from the Jada divestiture and new U.S. tax legislation.
The company entered a definitive agreement for Sun Pharma to acquire all shares for $14.00 per share in cash, approved by stockholders on July 23, 2026 and expected to close in early 2027, subject to regulatory and other customary conditions. In January 2026 Organon divested the Jada System for up to $465 million, including $440 million cash consideration and potential $25 million of contingent payments, recording an $81 million gain and a contingent consideration asset.
Organon ended June 30, 2026 with $1,132 million of cash and cash equivalents and total assets of $13,178 million. Total principal long‑term debt and short‑term borrowings were $8,553 million, with a weighted‑average interest rate of 4.9% and average maturity of 4.1 years. Six‑month operating cash flow was $332 million, aided by the Jada proceeds, while the company made $32 million of debt repayments and paid $11 million of dividends. Restructuring actions, including an approximate 3% headcount reduction, generated $31 million of severance‑related costs and left a $16 million severance liability.
Organon & Co. (OGN) reported lower sales but sharply higher profit for the quarter ended March 31, 2026 and agreed to be acquired. Revenue was $1.46 billion, down 4% as declines in Nexplanon, Singulair and some women’s health products outweighed growth in biosimilars and Emgality. Net income rose to $146 million from $87 million, helped by an $81 million gain on the sale of the Jada System and lower restructuring and interest expenses. Diluted EPS increased to $0.55 from $0.33.
Cash and cash equivalents climbed to $1.12 billion, while total principal debt was $8.57 billion with a 4.9% weighted-average interest rate. The company is executing a 3% headcount reduction and continues to carry substantial restructuring liabilities. The effective tax rate rose to 31.4% from 13.4%, reflecting U.S. tax law changes and mix of earnings.
Strategically, Organon divested the Jada System for up to $465 million and signed an exclusive global license for Miudella, a hormone‑free copper IUD, with up to $505 million in potential milestones. After quarter‑end, Sun Pharmaceutical Industries agreed to acquire all Organon shares for $14.00 per share in cash, with closing targeted for early 2027 subject to regulatory and stockholder approvals.
Organon & Co. reported Q3 2025 results with revenues of $1,602 million, up slightly from $1,582 million a year ago. Gross profit was $857 million. Net income was $160 million and diluted EPS was $0.61, compared with $359 million and $1.38 in Q3 2024. The effective tax rate was 34.0%.
Year to date, revenues were $4,709 million versus $4,811 million last year, with net income of $392 million. Operating cash flow reached $559 million for the first nine months. The company ended the quarter with cash and equivalents of $672 million, total assets of $13,552 million, long-term debt of $8,783 million, and stockholders’ equity of $906 million. In Q2 2025, Organon repurchased $242 million of 5.125% notes due 2031 and terminated a $103 million NovaQuest funding agreement, recording gains in other income.
Product highlights included Nexplanon/Implanon NXT $223 million and Vtama $34 million in the quarter. In September, the FDA approved Bildyos and Bilprevda (denosumab biosimilars) for all reference indications, with the EU also granting authorizations. The company declared a $0.02 per-share dividend in Q3 and reported a restructuring program initiated earlier in 2025.
Organon & Co. filed Amendment No. 1 to its Q2 2025 Form 10‑Q. The amendment updates MD&A disclosures regarding U.S. Nexplanon sales, restates Item 4 to reflect ineffective disclosure controls and procedures as of June 30, 2025 due to identified material weaknesses, amends a related risk factor, and replaces officer certifications. The company stated there will be no restatement or revision to previously issued financial statements.
Q2 2025 worldwide sales were $1.594 billion, down 1% year over year. For the first half, sales were $3.107 billion, down 4%. Q2 product highlights: Nexplanon $240 million (down 1%); Hadlima $50 million (up 78%); Ontruzant $31 million (down 35%); Atozet $86 million (down 38%); Singulair $66 million (down 29%); Vtama $31 million. Gross profit in Q2 was $874 million (down 7%).
Liquidity remained solid with cash and cash equivalents of $599 million and working capital of $1.82 billion as of June 30, 2025. Net cash from operating activities was $295 million for the first half. The company incurred $88 million in restructuring costs year‑to‑date and paid a $0.02 per share quarterly dividend. Organon acquired U.S. rights to Tofidence with a $51 million upfront payment, amortized over 10 years.
Organon & Co. filed Amendment No. 1 to its Q1 2025 Form 10‑Q to update disclosures following an internal review of Nexplanon wholesaler sales practices and to restate its controls conclusions. Management now reports material weaknesses in internal control over financial reporting and determined disclosure controls were not effective as of March 31, 2025. The company states no restatement or revision of previously issued financial statements is required.
Q1 results are unchanged: sales were $1.513 billion, down 7% year over year, with a $44 million headwind from foreign exchange. Segment highlights included Nexplanon revenue of $248 million (up 13%), Hadlima $47 million, and Atozet down 42% to $77 million. Operating items included $86 million of restructuring costs, with initiatives expected to deliver about $200 million in annual savings. Operating cash flow was $75 million; cash and equivalents were $547 million.
Other updates: the company acquired U.S. rights to Tofidence with a $51 million upfront payable in July 2025 (recognized as an intangible to be amortized over 10 years). The board declared a $0.02 quarterly dividend on May 1, 2025 after paying $0.28 per share in Q1.
Organon & Co. (OGN) Q2 2025 condensed summary: Revenues were $1.594 billion for the quarter and $3.107 billion for the six months, versus $1.607 billion and $3.229 billion in the prior-year periods. Net income fell to $145 million in Q2 2025 (Q2 2024: $195 million) and $232 million year-to-date (YTD 2025) versus $396 million YTD 2024. Diluted EPS was $0.56 for the quarter and $0.89 YTD versus $0.75 and $1.53 in the prior-year periods.
Key cash and balance sheet items: cash and equivalents declined to $599 million at June 30, 2025 from $675 million at Dec 31, 2024; total assets $13.5 billion; total long-term debt (net of current portion) $8.781 billion; weighted-average interest rate on borrowings 5.0% and average maturity ~5.1 years. Operating cash flow provided $295 million YTD; investing used $210 million, including Dermavant consideration.
Material corporate actions disclosed: Dermavant acquisition (aggregate consideration $581 million; contingent consideration fair value $383 million; $75 million regulatory milestone paid in Q1 2025); March 2025 U.S. rights for Tofidence from Biogen (intangible $51 million recognized; upfront paid in July 2025); July 2025 acquisition of Oss Biotech site (aggregate $25 million, $15 million paid). The Company repurchased $242 million of 5.125% 2031 notes in Q2, recording a $42 million pre-tax gain. The Company implemented restructuring reducing headcount ~6% and recorded $88 million of restructuring costs YTD. Effective tax rates increased (Q2 2025: 37.0% vs Q2 2024: 17.3%).